New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 8, 2013
10:32 EDTSIG, MON, CLMT, SHPG, IRE, MFCHigh options volume: SHPG MON MFC CLMT SIG IRE
News For SHPG;MON;MFC;CLMT;SIG;IRE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 25, 2015
15:34 EDTSIGNotable companies reporting before tomorrow's open
Subscribe for More Information
March 23, 2015
13:39 EDTMONMonsanto addresses assessment on glyphosate by IARC
Monsanto Company further addressed last week’s assessment on glyphosate by the International Agency for Research on Cancer. “We are outraged with this assessment,” said Dr. Robb Fraley, Monsanto’s Chief Technology Officer. “This conclusion is inconsistent with the decades of ongoing comprehensive safety reviews by the leading regulatory authorities around the world that have concluded that all labeled uses of glyphosate are safe for human health. This result was reached by selective ‘cherry picking’ of data and is a clear example of agenda-driven bias.” The repeated safety assessments by regulatory authorities over the last three decades have formed the foundation for the long history of safe, highly effective use of this important agricultural tool in more than 160 countries around the world. Decisions regarding product safety and approvals for pesticides are governed by regulatory agencies such as the U.S. Environmental Protection Agency and the European Commission, as well as independent scientific advisory bodies such as the European Food Safety Authority. IARC has no regulatory authority and its decision does not impact glyphosate’s label, current registration or use. “Safety is the top priority for every person who works at Monsanto. Glyphosate-based herbicides on the market meet the rigorous standards set by the regulatory and health authorities who work every day to protect human health, and we want our customers and consumers to be assured of these evaluations,” Fraley added. In contrast to the comprehensive review that regulators around the world have completed over three decades, IARC issued its classification based on a limited data review after hours of discussion at a one-week meeting. Further, IARC is one of four programs within the WHO that have reviewed the safety of glyphosate and their classification is inconsistent with the assessments of the other programs. Two of the WHO programs – the Core Assessment Group and the International Programme on Chemical Safety – both concluded glyphosate is not carcinogenic. The WHO Guidelines for Drinking-Water Quality program concluded glyphosate does not represent a hazard to human health.
12:17 EDTMONOn The Fly: Midday Wrap
Subscribe for More Information
11:21 EDTMONOrigin Agritech shares spike higher after report of possible takeover interest
Subscribe for More Information
11:07 EDTMONMonsanto weakness on Glyphosate WHO claims overblown, says Piper Jaffray
Subscribe for More Information
09:46 EDTMONScotts Miracle-Gro slips after report on Monsanto herbicide
Subscribe for More Information
09:45 EDTSHPGUBS to hold a field trip
Subscribe for More Information
09:37 EDTSHPGActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL AUY SLB PFE MCP CELG VRTX SHPG GILD LOGI TSLA TASR NFLX SCTY WFM
07:36 EDTSHPGPfizer should rise 'significantly' over next two years, says Jefferies
Jefferies analyst Jeffrey Holford told investors this morning that he expects shares of Pfizer (PFE) to appreciate "significantly" over the next two years. A survey of U.S. oncologists indicated the company's Ibrance drug will be used in 50% of first line hormonal therapy within one year, with off-label use in all lines of therapy including adjuvant, Holford noted. He thinks peak sales of the drug could top $13B, which is well above consensus. In addition, the analyst views Pfizer's Global Established Pharmaceutical business as being underappreciated by the market. Potential value creating options for the pharmaceutical giant include spinning off its GEP unit by 2017 and accretive acquisitions, with possible takeover targets being Shire (SHPG), Actavis (ACT), AstraZeneca (AZN) and GlaxoSmithKline (GSK), in the eyes of Holford. He added the stock to the firm's Franchise Picks list, which encompasses its best ideas. He also raised his price target for Pfizer to $45 from $42. The stock closed Friday up 10c to $34.25.
March 22, 2015
16:22 EDTMONChina looks to develop seed program to fend off foreign competition, WSJ says
Subscribe for More Information
14:27 EDTMONWHO says herbicide marketed by Monsanto likely carcinogenic, WSJ says
A World Health Organization agency said Friday that Glyphosate, a herbicide marketed by Monsanto under the Roundup brand and other companies, has the potential to cause cancer in humans, says the Wall Street Journal. Monsanto contested the findings saying that glyphosate is safe if used as recommended by its label and that decades of extensive study have proven its safety, added the Wall Street Journal. Reference Link
March 20, 2015
10:00 EDTSHPGOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:41 EDTSHPGBernstein global specialty pharma analyst holds analyst/industry conference call
Subscribe for More Information
08:12 EDTSHPGShire upgraded to Outperform from Market Perform at Bernstein
Bernstein upgraded Shire as the firm thinks that the stock's risk/reward ratio is positive following several new developments. Among these developments are the firm's belief that the company's orphan drug strategy looks increasingly strong, while the risks to the company's Vyvanse and mesalamines drugs look to have moderated and the company has several near-term, 2015 catalysts. Target $295.
March 18, 2015
14:37 EDTMONMonsanto and midwest, southeast wheat farmers reach settlement agreement
Subscribe for More Information
10:00 EDTCLMTOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:03 EDTSHPGTherapeuticsMD names Angus Russell, J. Martin Carroll as directors
TherapeuticsMD (TXMD) announced the appointment of two biopharmaceutical senior executives, Angus C. Russell and J. Martin Carroll, as independent members of its board of directors, and that Randall S. Stanicky has stepped down from the board of directors. Angus C. Russell served as CEO of Shire PLC (SHPG) from June 2008 until April 2013. J. Martin Carroll served as president and CEO of Boehringer Ingelheim Corp. U.S. from 2003 until 2011.
07:22 EDTSHPGShire looking for 'transformational' deal, Betaville blog says
Subscribe for More Information
06:44 EDTCLMTCalumet Specialty Products upgraded to Outperform from Sector Perform at RBC Capital
March 16, 2015
11:58 EDTMONDuPont retreats after Bank of America two notch downgrade to sell
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use